Company Overview
Snapshot
Founded in December 2021 by Or Shoval, Michal Tsur, and Shahar Shelly, Remepy operates with 51–200 employees. The company has raised $25 million across 4 funding rounds from 10 investors. In May 2026, Remepy reported strong Phase IIa clinical trial results for Hybridopa, its hybrid drug for Parkinson's disease.
Business overview
Remepy is a Health Tech & Life Sciences company pioneering hybrid drugs and redefining combination therapy to deliver personalized patient care. The company develops Digital Molecules, which are mobile applications designed for hybrid drug experiences, each containing a unique digital treatment protocol. These Digital Molecules include digitized, standardized, evidence-based interventions aimed at enhancing brain plasticity and connectivity, balancing the immune system, and driving behavioral changes. Remepy addresses disease endpoints, side-effects, and comorbidities, partnering with pharmaceutical companies to combine its Digital Molecule with traditional drug components.
Strategic signal
In April 2026, Remepy announced a collaboration with Merck KGaA, Darmstadt, Germany, to advance hybrid drugs across various therapeutic areas. This partnership signals significant industry validation for Remepy's innovative approach to combining software with medicine, potentially accelerating the development and market adoption of its hybrid drug pipeline and demonstrating a clear path for strategic growth through pharmaceutical collaborations.
Log in to access full profile ›Company Intelligence Q&A
- What were the key findings from Remepy's recent clinical trials for Hybridopa?
- In May 2026, Remepy reported strong Phase IIa clinical trial results for Hybridopa, its hybrid drug designed for Parkinson's disease. Further evidence published in July 2026 showed Hybridopa's effect on structural connectivity in the brain of Parkinson's patients, associated with improved clinical outcomes.
- Which company is Remepy collaborating with to advance hybrid drugs?
- In April 2026, Remepy announced a collaboration with Merck KGaA, Darmstadt, Germany, to advance hybrid drugs across various therapeutic areas, including rare tumor programs.
- What was the outcome of Remepy's mobile app study for subjective cognitive decline?
- In June 2025, Remepy's mobile app was shown to rewire the brain, modulate the immune system, and improve mood in adults with subjective cognitive decline.
- What was a significant leadership development at Remepy in early 2024?
- In February 2024, former Israeli Prime Minister Naftali Bennett joined Remepy's Board for its hybrid drug endeavor, uniting with co-founder and co-CEO Michal Tsur. However, in April 2026, Bennett resigned from Remepy's board.
- What is Remepy's strategy regarding artificial intelligence in its therapeutics?
- In June 2025, Remepy announced plans to embed AI in its next-generation digital therapeutics to enable personalized neuroimmune modulation.